Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives $35.75 Consensus PT from Brokerages

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been given an average rating of “Hold” by the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $35.75.

SNN has been the subject of several research reports. Royal Bank Of Canada downgraded shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Sanford C. Bernstein set a $37.50 target price on Smith & Nephew SNATS and gave the stock a “market perform” rating in a research report on Tuesday, October 14th. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 10th.

Institutional Investors Weigh In On Smith & Nephew SNATS

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Montreal Can lifted its position in shares of Smith & Nephew SNATS by 321.6% during the second quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock worth $105,056,000 after purchasing an additional 2,616,301 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Smith & Nephew SNATS by 6,663.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after buying an additional 1,192,755 shares during the last quarter. ABC Arbitrage SA grew its position in Smith & Nephew SNATS by 1,063.4% in the 2nd quarter. ABC Arbitrage SA now owns 898,635 shares of the medical equipment provider’s stock valued at $27,525,000 after buying an additional 821,393 shares during the last quarter. Todd Asset Management LLC purchased a new position in Smith & Nephew SNATS during the 3rd quarter valued at about $26,319,000. Finally, Goldman Sachs Group Inc. raised its holdings in Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after acquiring an additional 583,809 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Trading Down 0.5%

Shares of SNN stock opened at $32.71 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The firm has a 50-day moving average price of $32.97 and a 200 day moving average price of $34.28. Smith & Nephew SNATS has a twelve month low of $23.91 and a twelve month high of $38.79.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.